New hope for liver cancer: drug targets tumors resistant to immunotherapy
NCT ID NCT07151326
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers that predict response or resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib (Cabometyx®)
What this could lead to
If successful, this could provide a treatment option for liver cancer patients who no longer respond to standard immunotherapy combinations.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply broadly. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chang Gung Memorial Hospital (Lin-Kou),
Taoyuan, Taiwan
Contact
Contact
-
Chang-Gung Memorial Hospital, Kaohsiung
Kaohsiung City, Taiwan
Contact
Contact
-
China Medical University Hospital
Taichung, Taiwan
-
Mackay Memorial Hospital
Taipei, 104, Taiwan
Contact
Contact
-
National Cheng-Kung University Hospital
Tainan, Taiwan
Contact
Contact
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Contact
Contact
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
Contact
Contact
-
Taipei Veterans General Hospital
Taipei, Taiwan
Contact
Contact
-
Tri-Service General Hospital
Taipei, Taiwan
Contact
Contact